WELCOME TO The PHARMACEUTICAL REPORT
Johnson & Johnson
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Telegraph Media Group | January 26, 2017
Johnson & Johnson is buying blood pressure specialist Actelion in an all-cash deal that values the company at $30bn (£23.8bn), following months of complex negotiation and marking the first big pharmaceuticals transaction of the year....
Johnson & Johnson | May 10, 2017
Johnson & Johnson is under investigation by US authorities over marketing, rebates and payment support programmes, according to documents filed with the financial regulator....
Johnson & Johnson (JNJ) | June 08, 2017
Johnson & Johnson (JNJ) appears to be planning some big moves with its pharma pipeline. The company reportedly hired Merck (MRK)’s Mathai Mammen to helm J&J’s research and development unit. Mammen will replace Bill Hait who is taking over the reins of external innovation at J&J, Endpoints first reported this morning. According to the Endpoints report, Mammen will join Johnson & Johnson later this month, then assume the reins of the R&D unit in 2018....
Johnson & Johnson | July 26, 2017
Johnson & Johnson has announced encouraging first-in-human clinical data for an investigational HIV-1 vaccine regimen in development at its Janssen Pharmaceutical Companies. In an oral presentation of the early stage Phase 1/2a APPROACH study at the 9th IAS Conference on HIV Science (IAS 2017), the "mosaic"-based vaccine regimen from Janssen Vaccines & Prevention B.V. (Janssen) appeared to be well-tolerated and elicited HIV-1 antibody responses in 100% of healthy volunteers (n=393).
"Finding a ...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE